Patient-Derived Organoids Reveal Which Breast Tumors May Resist Standard Therapies

Lab-grown mini tumors help scientists predict breast cancer treatment success

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.

Patient-derived organoids reveal which breast tumors may resist standard therapies

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.

Can Miniature Organs Predict How Breast Tumors Respond to Treatment?

Researchers at the University of California, San Francisco, have developed a laboratory-based method that could help predict how individual breast tumors respond to cancer treatment. The approach combines molecular data from the I-SPY2 breast cancer trial with patient-derived organoids—three-dimensional “mini tumors” grown from a patient’s own cancer cells. In early testing, these organoids reproduced treatment […]

Lab-Grown Mini Organs Show Promise in Predicting Breast Cancer Treatment Outcomes

Senior study author Jennifer Rosenbluth, MD, PhD, (right) and study first author Tam Binh Bui, MSc, MD (left) working together in the Rosenbluth Lab at UCSF. Image courtesy of UCSF via Newswise Mega Doctor News by University of California, San Francisco (UCSF) Newswise — Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast …

Can Mini Organs Help Predict Breast Tumors’ Response to Therapy?

In a study in Cell Reports Medicine, UCSF researchers found that organoids were able to mimic a tumor's response to treatment. They demonstrated that organoid responses to a combination of therapies matched response predictions from biomarker and clinical trial data, and subtype-specific drug screening identified candidate breast cancer therapies for further investigation.